日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The impact of clinical manifestations on the prognosis of diffuse large B-cell lymphoma

临床表现对弥漫性大B细胞淋巴瘤预后的影响

Wang, Siqian; Xu, Xi; Ma, Yongyong; Qian, Shanhu; Tang, Liyuan; Sun, Lan; Shen, Zhijian; Ye, Haige; Qian, Honglan; Jiang, Songfu; Zhou, Shujuan

miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting

miR-182启动子高甲基化可预测真实世界中接受AZA+VEN治疗的AML患者的更佳预后

Xu, Yilan; Li, Danyang; Wang, Na; Ge, Bei; Meng, Chen; Zhao, Min; Lin, Zihan; Li, Min; Yuan, Yigang; Cai, Yue; Shi, Liuzhi; Gao, Shenmeng; Ye, Haige

[Retracted] IQGAP1 plays an important role in the cell proliferation of multiple myeloma via the MAP kinase (ERK) pathway

[已撤稿] IQGAP1 通过 MAP 激酶 (ERK) 通路在多发性骨髓瘤细胞增殖中发挥重要作用

Ma, Yongyong; Jin, Zhouxiang; Huang, Jin; Zhou, Shujuan; Ye, Haige; Jiang, Songfu; Yu, Kang

POD24-Based prognostic signature enables personalized risk stratification in mantle cell lymphoma

基于POD24的预后特征可实现套细胞淋巴瘤的个体化风险分层

He, Yizi; Wang, Caiqin; Pan, Tao; Cai, Qingqing; Zhou, Dehui; Zhang, Huilai; Liang, Rong; Zeng, Dongfeng; Ye, Haige; Liang, Yun; Sun, Xiuhua; Xiao, Ling; Zhou, Hui

The efficacy and safety of ZR2 versus R-CHOP-like for elderly patients with newly diagnosed diffuse large B cell lymphoma: a single-center prospective study in China

ZR2方案与R-CHOP样方案治疗老年新诊断弥漫性大B细胞淋巴瘤患者的疗效和安全性:一项中国单中心前瞻性研究

Jiang, Panruo; Li, Rongqi; Li, Hui; Xu, Yilan; Xu, Zhenyan; Xing, Chongyun; Yu, Kang; Jiang, Songfu; Zhang, Xiuhua; Ye, Haige

Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

抗CD47抗体在血液系统恶性肿瘤治疗中的机遇与挑战

Xu, Yilan; Jiang, Panruo; Xu, Zhenyan; Ye, Haige

Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China

在中国,来那度胺联合R-CHOP方案治疗弥漫性大B细胞淋巴瘤的成本效益分析

Li, Rongqi; Zeng, Yuhan; Chen, Yizhang; Ye, Zhongjiang; Chen, Chuang; Yang, Jianhui; Fu, Jing; Zhou, Tao; Jiang, Danna; Qin, Sunting; Ye, Haige; Zhou, Ziye; Zhang, Xiuhua

Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.

PI3K 和 BCL-2 的双重靶向作用可克服侵袭性套细胞淋巴瘤的伊布替尼耐药性

Ye Haige, Huang Shengjian, Liu Yang, Chen Zhihong, Wang Michael, Jiang Vivian Changying

Spontaneous regression of mantle cell lymphoma: a report of four cases

套细胞淋巴瘤自发性消退:四例报告

Ye, Haige; Desai, Aakash; Gong, Tiejun; Zeng, Dongfeng; Nomie, Krystle; Chen, Wendy; Wang, Wei; Romaguera, Jorge; Wang, Michael L

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

对于年轻且身体状况良好的套细胞淋巴瘤患者,首选治疗方案:一线治疗策略

Ye, Haige; Desai, Aakash; Huang, Shengjian; Jung, Dayoung; Champlin, Richard; Zeng, Dongfeng; Yan, Fangfang; Nomie, Krystle; Romaguera, Jorge; Ahmed, Makhdum; Wang, Michael L